Article: Strong results for ALK-Abello's Grazax.(allergy vaccinations)(Brief Article)

Denmark-based ALK-Abello, a leading developer of allergy vaccinations in Europe, says that clinical data on Grazax, its oral immunotherapy for grass pollen allergies, show that it reduces the symptoms of hay fever 30% and also causes a 38% drop in the need for symptom-relieving medication.

The 634-patient GT-08 study confirmed the optimal dose of 75,000 SQ-T and also found that patients on the tablets experienced an improved quality of life.

...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!